Spherix Global Insights

March 15, 2017

RealTime Dynamix™: Bone and Mineral US Q1

The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market.

This monthly report series focuses on tracking key performance metrics for phosphate binders, calcimimetics and vitamin D agents in both the dialysis and CKD-ND settings. Emphasis is placed on recently launched products (Rayaldee and Parsabiv) and pipeline agents such as Amgen’s Ardelyx’s tenapanor. The rapid field-to insight turnaround, highly relevant content and unparalleled market understanding make RealTime Dynamix™ an essential tool for companies with commercial products in the space, those that will soon be launching and those looking for business development opportunities in nephrology.

Download Report Overview

About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Telephone: (800) 661-0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com